ANGOHIGH SIGNALFINANCIAL10-K

AngioDynamics showed substantial improvement in profitability with losses meaningfully reduced across both net income and operating income metrics.

The company appears to be executing a successful turnaround strategy, with losses substantially narrowing while maintaining disciplined cost management through reduced R&D spending. The improved operational performance, combined with better cash flow generation, suggests management's restructuring efforts are gaining traction.

Comparing 2025-07-18 vs 2024-07-25View on EDGAR →
FINANCIAL ANALYSIS

AngioDynamics demonstrated marked financial improvement with losses substantially reduced on both the net income and operating income lines, while operating cash flow also improved meaningfully. The company maintained cost discipline with R&D expenses declining 16.8% and overall liabilities decreasing across current and total metrics. While cash and equivalents declined 26.5% and total assets contracted 11.8%, the dramatic improvement in operational performance suggests the company is successfully executing its turnaround strategy and moving toward profitability.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+81.6%
-$184.3M-$34.0M

Net income grew 81.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+79.2%
-$192.4M-$40.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
+77.3%
$2.5M$4.5M

Capital expenditure jumped 77.3% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+64%
-$28.2M-$10.1M

Operating cash flow surged 64% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
-26.5%
$76.1M$55.9M

Cash decreased 26.5% — monitor burn rate and upcoming capital needs.

R&D Expense
P&L
-16.8%
$31.5M$26.2M

R&D spending cut 16.8% — could signal cost discipline or concerning reduction in innovation investment.

Current Liabilities
Balance Sheet
-16.4%
$91.2M$76.2M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-13.3%
$112.1M$97.2M

Liabilities reduced 13.3% — deleveraging improves balance sheet strength and financial flexibility.

Current Assets
Balance Sheet
-12.9%
$193.3M$168.3M

Current assets declined 12.9% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-11.8%
$317.7M$280.1M

Total assets contracted 11.8% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-07-18
PRIOR — 2024-07-25
ADDED
As of July 16, 2025 there were 40,633,885 shares of the registrant s common stock outstanding.
OVERVIEW AngioDynamics is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing and selling products and technologies which aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses.
Our execution strategy is built on innovative R D, clinical and regulatory pathway expansion and customer centric sales performance.
On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc.
On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC.
+7 more — sign up free →
REMOVED
As of July 24, 2024 there were 40,276,582 shares of the registrant s common stock outstanding.
OVERVIEW AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients.
On December 17, 2019, the Company acquired the C3 Wave tip location asset from Medical Components Inc., which the Company sold in February 2024 to Spectrum Vascular pursuant to an asset purchase agreement.
On July 27, 2021, AngioDynamics acquired the Camaro Support Catheter asset from QX Medical, LLC and subsequently discontinued this product in the third quarter of fiscal year 2024.
The Auryon system is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →